

CURRICULUM VITAE
John William Kelly, M.D.

CURRENT BUSINESS ADDRESSES:

Greenville Health System
Infectious Disease Associates
890 W. Faris Road, Suite 520
Greenville, SC 29605

EDUCATION:

- 1988 Walter Reed Institute of Tropical Medicine
 Washington, D.C.
- 1985-1987 Fellowship - Infectious Diseases
 Brooke Army Medical Center
 Fort Sam Houston, Texas
- 1982-1984 Residency - Internal Medicine
 Methodist Hospital
 Memphis, Tennessee
- 1981-1982 Internship - Straight Medicine
 Methodist Hospital
 Memphis, Tennessee

POSTGRADUATE TRAINING

- 1981 University of Mississippi
 Jackson, Mississippi
 Doctor of Medicine
- 1977 University of Mississippi
 Oxford, Mississippi
 B.S. - Civil Engineering

ACTIVE LICENSURE:

1994-present South Carolina

BOARD CERTIFICATION:

1988 Infectious Diseases
1986 Internal Medicine

EMPLOYMENT AND APPOINTMENTS:

2015- present Adjunct Professor of Biomedical Sciences - Microbiology
 University of South Carolina School of Medicine-Greenville
 Greenville, South Carolina

2012-present Clinical Professor, Infectious Diseases
 University of South Carolina School of Medicine-Greenville
 Greenville, South Carolina

2011-2015 Clinical Professor of Biomedical Sciences - Microbiology
 University of South Carolina School of Medicine-Greenville
 Greenville, South Carolina

2010-present Infectious Disease Specialist
 Easley Baptist Hospital - Easley, South Carolina

2004-present Professor of Clinical Internal Medicine
 University of South Carolina School of Medicine-Greenville
 Greenville, South Carolina

2004-present Infectious Disease Specialist
 Regency Hospital - Greenville, South Carolina

2000-2001 Director of Research, Department of Internal Medicine
 Greenville Hospital System - Greenville, South Carolina

1999-present Hospital Epidemiologist
 Greenville Health System - Greenville, South Carolina

1998-2009 Chairman, Institutional Animal Use and Care Committee
 Greenville Hospital System - Greenville, South Carolina

1997-2001 Resident Evaluation Committee, Department of Internal Medicine
 Greenville Hospital System - Greenville, South Carolina

1999-2000 Medical Director, Clinical Trials Management Office
 Greenville Hospital System - Greenville, South Carolina

John William Kelly, M.D.

Curriculum Vitae

Page 3 of 14

- 1996-2004 Associate Professor of Medicine
University of South Carolina School of Medicine
- 1996-2000 Academic Chairman, Transitional Residency Program
Greenville Hospital System - Greenville, South Carolina
- 1995-1997 Chairman, Ward/Night Call Committee
Internal Medicine Residence Program, Greenville Hospital System, Greenville
South Carolina
- 1995-1996 Assistant Professor of Medicine
University of South Carolina School of Medicine
Greenville, South Carolina
- 1995-2000 Biomedical Associate Professor
Clemson University - Clemson, South Carolina
- 1994-1997 Member, Scientific Review Committee
Member, Institutional Review Board
Greenville Hospital System, Greenville, South Carolina
- 1994-present Infectious Disease Specialist
University Medical Group- Department of Medicine
Greenville Health System - Greenville, South Carolina
- 1994-present Hospital Epidemiologist
Easley Baptist Hospital - Easley, South Carolina
- 1994-present Infectious Disease Specialist
Bon Secours Saint Francis Hospital - Greenville, South Carolina
- 1994-1997 Board Member, AID Upstate, Greenville, South Carolina
- 1992-1994 Consultant, Bone Marrow Transplant Unit, Brooke Army Medical Center, Fort
Sam Houston, Texa
Member, Clinical Investigation Committee, Brooke Army Medical Center, Fort
Sam Houston, Texas
- 1992-1994 Member, Operations Committee, Military Medical Consortium for Applied
Retroviral Research
- 1993-1994 Member, Persian Gulf Task Force, U.S. Army

AWARDS AND HONORS

- 2013– 2014 Teacher of the Year – Biomedical Sciences (Microbiology)
University of South Carolina School of Medicine - Greenville
Greenville, South Carolina
- 1994– 1995 Teacher of the Year - Internal Medicine Residency Program
Greenville Hospital System
Greenville, South Carolina
- 1976– 1977 Chi Epsilon, Chapter President
University of Mississippi
- 1972– 1977 University Scholar
University of Mississippi
- 1972– 1976 L.O. Crosby Scholar
University of Mississippi
- 1976 Tau Beta Pi, Chapter President
University of Mississippi

PROFESSIONAL ORGANIZATIONS

- 1987 – present American College of Physicians
- 1993 – present Infectious Diseases Society of America
- 2000 – present Society for Healthcare Epidemiology for America
- 1994 – present South Carolina Infectious Diseases Society
- 1984 – present Shogun Medical Society, Japan
- 1985 – present 38th Parallel Medical Society, Korea
- 1994 – 1998 American Federation for Medical Research
- 1981 – 2000 American Medical Association
- 1994 – 2001 South Carolina Medical Association
- 1994 – 2000 Greenville County Medical Society

GRANTS:

Extramural Grants:

- 1990 -1991 VA CSP 316 - Immunoprophylaxis of Kleibsiella and Pseudomonas
Infections (Department of Veterans Affairs) \$45,000. (15% Time).
- 1991 -1993 Comparison of Cefipime and Ceflazidime in the Treatment of Gram Negative
Bacteremia (Bristol-Meyers Squibb) \$62,000. (10% Time).
- 1992 -1994 A Double-Blind Placebo-Controlled Parallel Group Multicenter Study of the
Prophylaxis of Mycobacterium Avium Complex Infection in Late Stage HTV
Patients (Pfizer) \$4,000. (5% Time).

- 1996-1971 R43 AR 43917-01 - Absorbable Gels for Controlled Release of Antibiotics (National Institutes of Health) \$99,000. (10% Time).
- 1999 Pharmacokinetics and Safety of Seven Days Intravenous Intraconazole Nanocrystals in Intensive Care Unit Subjects (Jansen) \$88,000. (10% Time).
- 2001-2002 Prevention of Infections Related to Central Venous Catheters and Arterial Catheters in Intensive Care Patients: A Prospective Randomized Trial of Chrorhexidine, Gluconate (CHE) Versus Povidone Iodine (PI) for Skin Antisepsis and Catheter Care (Med-Flex) \$43,000 (5% time).
- 2007-2015 Development of Electronic Hand-Hygiene Monitoring System (DebMed) \$300,000.

Intramural Grants/Awards:

- 1989 -1990 Gastric Hyposecretion in Patients with HTV-1 Infection. \$1,000.00
- 1992 Ketoconazole Absorption in HIV Patients. \$2,000.00.
- 1993 Effect of Thyroid Hormone on HIV Infected Cells. \$3,000.00
- 1994 An Experimental Rat Model of Post-Pneumonic Empyema. \$4,500.00.
- 1995 Pilot Studies of Polymer Based Antimicrobial Delivery Devices \$5,000

PRESENTATIONS:

1. Kelly JW, Blackhurst DW, Boeker S, Steed CJ. Handy Hygiene Compliance: Is Measurement of “In/Out” Comparable to the WHO 5-Moments and Does it Truly Reflect the Risk to Patients. Society of Healthcare Epidemiology of America Spring Meeting. Atlanta, Georgia, May 2016.
2. Kelly JW, Diller T, McAtee W, Boeker S, Steed CJ, Blackhurst DW. Use of Targeted Solutions Tool and Electronic Monitoring to Improve Hand Hygiene Compliance. ID Week 2016. New Orleans, Louisiana, October 2016
3. Kelly JW. An Outbreak of Mycobacterium abscessus Infections in Surgical Patients. South Carolina Infectious Disease Society – Columbia, SC, January 2015.
4. Robinson, N, Boeker S, Steed CJ, Kelly JW. Innovative Use of Electronic Hand Hygiene Monitoring to Control a Clostridia difficile Cluster on a Hematopoetic Stem Cell transplant Unit. Association of Professionals in Infection Control and Epidemiology 41st Annual Conference and Educational Meeting, Anaheim CA, June 2014.

5. Steed CJ, Kelly JW, Blackhurst DW, Boeker S, Alper P, Larson E: Hospital Hand Hygiene Opportunities Where and How (HOWZ). First International Conference on Prevention and Infection Control (ICPIC), Geneva, Switzerland, June 2012.
6. Cass A, Kelly JW, Probst C, Addy C, McKeawn R: Identification of Device Associated Infections Utilizing Administrative Data. 3rd North American Congress of Epidemiology. Montreal, Canada, June 2011
7. Kelly JW, Usry G, Bushey M, Blackhurst D, Steed C: Prevention of Infections Related to Central Venous Catheters and Arterial Catheters in Intensive Care Unit Patients. Society for Healthcare Epidemiology of America 15th Annual Meeting, Los Angeles, CA, April 2005.
8. Usry G, Steed CJ, Kelly JW: Infection Prevention of Methicillin-Resistant *Staphylococcus aureus* in a Neonatal Intensive Care Unit. Association for Professionals in Infection Control and Epidemiology 31st Annual Educational Conference and International Meeting, Phoenix, AZ, June 2004.
9. Adult Immunizations, OB-GYN Grand Rounds, Greenville Hospital System, Greenville, SC, March 2003.
10. Bioterrorism South Carolina Society of Hospital Pharmacists Regional Meeting, Anderson, SC, February 2003.
11. Steed C, Usry G, Kelly JW: Control of an Outbreak of Antibiotic Resistant *Acinetobacter Baumannii*. in an Intensive Care Unit. Association for Professionals in Infection Control and Epidemiology 29th Annual Educational Conference and International Meeting, Nashville, TN, May 2002.
12. Westberry DE, Rudisill ER, Kelly JW: Mycobacterium Terrae Tenosynovitis Associated with Spurring of a Gaming Rooster (Poster). American Orthopedic Association 33rd Annual Residents Conference, St. Louis, MO, February 2000.
13. Penicillin Resistant Pneumococcal Infections, Medical Grand Rounds, Anderson Areas Medical Center, Anderson, SC, December 1998.
14. Corbett JT, Jerome JF, Kelly JW, et al: New Injectable, Absorbable Controlled Release System for Treating Osteomyelitis. 44th Annual Meeting, Orthopedic Research Society, New Orleans, LA, March 1998.
15. Oldfield EC, Dickinson G, Chung R, et al. Once Weekly Azithromycin for the Prevention of Mycobacterium avium Complex (MAC) Infection in AIDS Patients. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, D.C., February 1998.
16. Corbett Jt, Jerome JE, Allan J, Kelly JW, et al.: In vitro and In vivo Release of Vancomycin and Gentamicin from an Injectable Absorbable Gel-Forming Matrix for the Treatment of Osteomyelitis. Materials Research Society Fall Meeting, Boston, MA, December 1997.
17. Tick-Borne Illness. Medical Grand Rounds, Eisenhower Army Medical Center, Ft. Gordon, GA, December 1996.

18. Krüger E, Kelly JW, Gray BH, Kelley RN, Benjamin D: The Impact of Undervaccination on Invasive Infections due to Penicillin-resistant Pneumococci. American College of Physicians South Carolina Associates Meeting, Greenville, SC, September 1996. (Winning research paper.)
19. Kelly JW, Weems JJ, Hansen M, Pace TB, Ridgeway SR: Nephrotoxicity Due to Use of Antibiotic Impregnated Cement in Orthopedic Surgery. Infectious Diseases Society of America Annual Meeting, New Orleans, LA, September 1996.
20. Schwab U, Kelly JW, Weems JJ: Genetic Analysis of Clinical Isolates of *Bacillus cereus* by Pulse-Field Gel Electrophoresis. 96th General Meeting of the American Society of Microbiology, New Orleans, LA, May 1996.
21. Bizzell S, Tiffany J, Kelly JW: Are Stethoscopes Vectors of Infection in Intensive Care Units? 1996 American College of Physicians Annual Session, San Francisco, CA, April 1996. (Associate Paper Competition Finalist.)
22. Krüger E, Kelly JW, Gray BH, Kelley RN, Benjamin D: The Impact of Undervaccination on Invasive Infections Due to Penicillin-Resistant Pneumococci. 1997 American College of Physicians Annual Session, Philadelphia, PA, March 1996. (Associates Paper Competition Finalist.)
23. Bizzell S, Tiffany J, Kelly JW: Are Stethoscopes Vectors for Infection in Intensive Care Units? 1995 American College of Physicians South Carolina Associates Meeting, Columbia, SC, September 1995. (Winning research paper.)
24. Srivastava, V, Weems JJ, Kelly JW: Eosinophilic Distal Gangrene in a Patient with AIDS. 1995 American College of Physicians South Carolina Associates Meeting, Columbia, SC, September 1995. (Winning clinical vignette.)
25. Tick-Borne Illness. South Carolina Medical Association Annual Meeting, Charleston, SC, May 1995.
26. The Biotechnology Challenge of Infectious Diseases. Medical Textiles and Biomedical Polymers and Materials Conference. Greenville, South Carolina. September 1994.
27. Caring for Men with HIV/AIDS. SC AIDS – Clinical Management Issues. South Carolina AIDS Training Network. Greenville, South Carolina. September 1994.
28. Dooley D, Garcia JW, Longfield RN, Kelly JW, Harrison L: Validation of the Catheter Semiquantitative Culture Technique for Non-Staphylococcal Organisms (Poster). 1994 Infectious Diseases Society of America Annual Meeting, Orlando, FL, October 1994.
29. Carlin K, Anderson S, Kennedy R, Chapa I, Kelly JW, Thomason A, Carlin S: Normal Cells Infected with HIV In Vitro are Independent of Thyroid Hormone (Poster). First National Conference on Human Retroviruses and Related Infections, Washington, D.C., December 1993.
30. Morris JT, Kelly JW, Mazurek G, Koch J, Wallace RW: Homeless Shelters as a Point Source for Tuberculosis (Poster). 1993 Infectious Diseases Society of America Annual Meeting, New Orleans, LA, October 1993.

31. Schrank JH, McAllister CK, Kelly JW, Morris JT: Comparison of Cefipime and Ceftazidime in the Treatment of Gram Negative Bacteremia (Poster). 1993 Infectious Diseases Society of America Annual Meeting, New Orleans, LA, October 1993.
32. Morris JT, Kelly JW, Merrill G, McAllister CK: Ketoconazole Absorption in HIV Patients (Poster). 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 1993.
33. Birx DL, Redfield RR, Davis C, Ruiz N, Wagner K, Johnson JW, Kelly JW, Sun W, Aronson N, Oster C, Lennox J, Burke D, and the MMCARR: Active Immunization of AZT-Treated HIV-1 Infected Patients with Recombinant rGP160(MG5) (Poster). Conference on AIDS Vaccine Development; Sixth NCVDE Meeting, Chantilly, VA, September 1993.
34. Top 10 STD's, Medical Grand Rounds, Letterman Army Medical Center, San Francisco, California, April 1989.
35. Longfield RN, Hawkes CA, Longfield JL, Kelly JW, Slagle DS, McAllister CK: The Prospective Evaluation of Asymptomatic Patients Seropositive for the Human Immunodeficiency Virus (Poster). Southern Section American Federation for Clinical Research, New Orleans, LA, February 1988.

PUBLICATIONS

1. Kelly JW, Blackhurst DW, Steed CJ, Diller T. A Response to the Article "Comparison of Hand Hygiene Monitoring Using the 5 Moments for Hand Hygiene Method versus a Wash-in Wash-out Method (letter). *American Journal of Infection Control*, 2015 Aug; 901-902 doi:10.1016/ajic2015.02.032.
2. Diller T, Kelly JW, Blackhurst DW, Steed CJ, Boeker S, McElven DC. Estimation of Hand Hygiene Opportunities on a Medical Ward Using 24-hour Camera Surveillance: Validation of the Howz Benchmark Study. *American Journal of Infection Control* 42(6): 602-7, 2014. Doi:10.1016/ajic2014.02.020.
3. Cars AL, Kelly JW, Probst JC, Addy CL, McKeown RE: Identification of Device Associated Infections Using Administrative Data. *American Journal of Infection Control*, 41(12): 1195-9, 2013. Doi:10.1016/jajic20113.03.295.
4. Diller T, Kelly JW, Blackhurst D, et al. estimation of Hand Hygiene Opportunities on an Adult Medical Ward Using 24-Hour Camera Surveillance: Validation of the HOW2 Benchmark Study. *American Journal of Infection Control*. 42(6): 602-607, 2014.
5. Cass AL, Kelly JW, Probst JC et al. Identification of Device-associated Infections Utilizing Administrative Data. *American Journal of Infection Control*. 41 (12): 1195-1199, 2013

6. Steed CJ, Kellw JW, Blackhurst DW, Boeker S, Diller T, Alper P, Larson E: Hospital Hand Hygiene Opportunities: Where and When (HOWZ)? The HOWZ Benchmark Study. *American Journal of Infection Control*, 39:19-26, 2011.
7. Boeker S, Drociuk D, Jankelevich S, Kelly JW, Steed CJ: Mutual benefits in Partnerships between Hospital-based and Public Health Department Syndromic Surveillance Systems in Outbreak Detection and Investigation. *Advances in Disease Surveillance*, 4:146-147, 2007.
8. Brown AF, Dolan MJ, Michael NI, et al.: Clinical Prognosis of Patients with Early Stage Human Immunodeficiency Virus (HIV) Disease: Contribution of HIV-1 RNA and T-Lymphocyte Subset Quantitation. *Military Medicine*, 166:517-576, 2001.
9. Birx DL, Loomis-Price LD, Aronson N, et al.: Efficacy Testing of Recombinant Human Immunodeficiency Virus (HIV) gp160 as a Therapeutic Vaccine in Early Stage HIV-1-1 Infected Volunteers. *Journal of Infectious Diseases*, 181:881-889, 2000.
10. Oldfield EC III, Fessell WJ, Dunne MW, et al.: Once Weekly Azithromycin Therapy for Prevention of *Mycobacterium avium* Complex Infection in Patients with AIDS: A Randomized, Double Blind, Placebo Controlled, Multicenter Trial. *Clinical Infectious Diseases*, 26:611-619, 1998.
12. Donta ST, Peduzzi P, Cross AS, et al.: Immunoprophylaxis against *Klebsiella* and *Pseudomonas aeruginosa* Infections. *Journal of Infectious Diseases*, 174:537-544, 1996.
13. Dooley DP, Garcia A, Kelly JW, Longfield RN, Harrison L: Validation of Catheter Semiquantitative Culture Technique for Nonstaphylococcal Organisms. *Journal of Clinical Microbiology*, 34: 409-412, 1996.
14. Wong, MT, Dolan MJ, Lattuada CP, Regnery RL, Garcia ML, Mokulus EC, LaBarre RC, Ascher DP, Delmar J, Kelly JW: Neuroretinitis, Aseptic Meningitis and Lymphadenitis in Immunocompetent and HIV-I Infected Patients Associated with *Rochalimaea (Bartonella) henselae* Infection. *Clinical Infectious Diseases*, 21:352-360, 1995.
15. Schrank JH, Kelly JW, McAllister CK, Morris JT: Comparison of Cefipime and Ceftazidime in the Treatment of Gram Negative Bacteremia. *Clinical Infectious Diseases*, 20: 56-58, 1995.
16. Kelly JW, Morris MJ: Empyema Thoracis: Medical Aspects of Management. *Southern Medical Journal*, 87:1103-1110, 1994.
17. Morris JT, Kelly JW: Rifabutin-induced Ageusia. *Annals of Internal Medicine*, 119: 171-172, 1993.

18. Dooley DP, Hodges SD, Kelly JW: Factitious Infections in Orthopedic Patients. *Clinical Orthopedics*, 16: 816-819, 1993.
19. Shaffer RT, LaHatte LJ, Kelly JW, et al: Gastric Acid Secretion in HIV-1 Infection. *The American Journal of Gastroenterology*, 87: 1777-1780, 1992.
20. Kelly JW, Dooley DP, Lattuada CP, Smith CE: A Severe Unusual Reaction to Trimethoprim-Sulfamethoxazole in HIV-Infected Patients. *Clinical Infectious Diseases*, 14: 1034-1039, 1992.
21. Morris JT, Kelly JW: Recurrence of Neisseria Meningococemia Due to Deficiency of Terminal Complement Component (C6). *Southern Medical Journal*, 85: 1030-1031, 1992.
22. Morris JT, Kelly JW: Effective Treatment of Cerebral Toxoplasmosis with Doxycycline. *American Journal of Medicine*, 93: 107, 1992.
23. Oulette DR, Kelly JW, Anders GT: Serum Angiotensin Converting Enzyme is Elevated in Patients with Human Immunodeficiency Virus Infection. *Archives of Internal Medicine*, 152: 321-324, 1992.
24. Battafarano DF, Jefferies B, McAllister CK, Kelly JW: The Lack of Utility of the Latex Agglutination Test for Detection of Candida Antigen in the Diagnosis of Systemic Candidiasis. *Military Medicine*, 156: 283-5, 1991.
25. Deppe SA, Kelly JW, Thoi LL, et al: Incidence of Colonization and Nosocomial Pneumonia in Critically Ill Patients Using Trach-Care Multiple Use Suction System Versus a Disposable Suction System: A Prospective, Randomized Study. *Critical Care Medicine*, 18: 1389-1393, 1990.

Chapters in Scholarly Books and Monographs:

1. Kelly JW: Bacterial Meningitis. In Rakel RE and Bope ET (eds.): 2005 Conn's Current Therapy, pp. 125-128. Philadelphia: Elsevier, Inc., 2005.
2. Kelly JW: Bacterial Meningitis. In Rakel RE (ed.): 1994 Conn's Current Therapy, pp. 100-103. Philadelphia: W.B. Saunders Company, 1994.
3. Kelly JW, McAllister CK: Syphilis. In Harwood-Nuss, A.L., et al. (eds): *The Clinical Practice of Emergency Medicine*, Vol. 1, pp. 1045-1048. Philadelphia, J.B. Lippincott Company, 1991.

RESEARCH TRAINING:

- 2013 Collaborative Institutional Training Initiative (refresher course)
- 2011 Collaborative Institutional Training Initiative (refresher course)
- 2009 Collaborative Institutional Training Initiative (refresher course)

- 2007 Collaborative Institutional Training Initiative
- 2001 Human Subject Research Education
Greenville Hospital System
Office of Research Compliance and Administration

CLINICAL TRIALS EXPERIENCE

1. Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections. **Co-investigator**
2. A Multicenter, 2-Cohort Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Subjects with Staphylococcus aureus Bacteremia or with Persistent Methicillin-Resistant Staphylococcus aureus. **Co-investigator**
3. A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Patients with Blood Stream Infections due to Staphylococci. **Co-investigator**
4. Validation Study of Estimated Hand Hygiene Opportunities in Hospital Setting. **Co-Principal Investigator**
5. A Phase 3 Randomized, Double Blind, Multinational Trial of Intravenous Telavancin versus Vancomycin for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections with a Focus on Patients with Infections Due to Methicilin-resistant *Staphylococcus aureus*. **Co-investigator**
6. A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults. **Principal Investigator**
7. A Randomized, Double-Blind Study of GT267-004 versus Vancomycin, and GT267-004 versus Metronidazole, in Patients with *C. difficile*-Associated Diarrhea. **Co-investigator**
8. A Phase 3, Multi-Center, Randomized, Double-Blind, Comparative Study of the Efficacy and Safety of Tigecycline vs. Imipenem for the Treatment of Subjects with Nosocomial Pneumonia. **Co-investigator**
9. A Phase 3, Multi-Center, Randomized, Double-Blind, Comparative Study of the Efficacy and Safety of Tigecycline vs. Levofloxacin to Treat Subjects Hospitalized with Community-Acquired Pneumonia. **Co-investigator**
10. A Multicenter, Double Blinded, randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous Doripenem and Levofloxacin in Complicated Lower Urinary Tract Infection or Pyelonephritis. **Co-investigator**

11. A Multicenter, Randomized, Double Blind Comparison of the Safety and Efficacy of Tigecycline with those of Vancomycin to Treat Complicated Skin and Skin Structure Infections in Hospitalized Patients. **Co-investigator**
12. A Phase II, Randomized, Double-blind, Multi-center Clinical Trial Comparing Safety and Pharmacokinetics of Standard of Care, Plus Tefibazumab or Placebo, for Treatment of *Staphylococcus aureus* bacteremia (SAB) **Co-investigator**
13. A phase III, Multi-center, Randomized, Open-label, Comparative Study to Assess the Safety and Efficacy of Daptomycin Compared to Conventional Therapy in the Treatment of Subjects with Infective Endocarditis or Bacteremia due to *Staphylococcus aureus*.
Co-investigator
14. Cubicin for Complicated Post-surgical Infections. **Co-investigator**
15. Prospective Randomized, Open-labeled, Multicentre Trial Comparing the Safety and Efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in Three-class (NRTI, NNRTI and PI) Treatment Experienced Patients with Resistance to more than One PI. **Co-investigator**
16. A phase IV, Multicenter, Cross-Sectional Study to Evaluate I50L Substitution Among Subjects Experiencing Virologic Failure on HAART Regimen Containing Atazanavir (ATV). **Co-investigator**
17. Observational Cohort Study of Pneumonia in Fuzeon-exposed and Non-exposed Patients.
Co-investigator
18. A Phase 3, Randomized, Open-label Study of Lopinavir/Ritonavir Tablets 800/200 mg Once-daily versus 400/100 mg Twice-daily when Co-administered with Nucleoside/Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral-experienced, HIV-1 Infected Participants. **Co-investigator**
19. Early Access of MK-0518 in Combination with an Optimized Background Antiretroviral Therapy in Highly Treatment Experienced HIV-1 Infected Patients with Limited to No Treatment Options. **Co-investigator**
20. A Multicenter, randomized, Double-blind Placebo Controlled Trial of Novel CCR5 Antagonist, UK-427,857 in Combination with Optimized Background Therapy versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-experienced HIV-1 Infected Subjects. **Co-investigator**
21. Evolution of L74V or K65R Mutations in Viremic Subjects on TDF or ABC (EVITA).
Co-investigator
22. A Phase IIIB, Randomized, Open-Label, Multi-center, Parallel-Arm Study to Evaluate the Short-Term Safety and Tolerability of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered Once-Daily or the Separate Abacavir and Lamivudine Tablets Administered Twice-Daily, as Part of a Three or Four Drug Regimen, in Antiretroviral-Naïve HIV-1 Infected Subjects. **Co-investigator**

23. A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908/Ritonavir given with Abacavir/Lamivudine Fixed Dose Combination.
Co-investigator
24. A Phase IB Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, And Pharmacokinetics Of Multiple Oral Doses Of KP-1461 In HIV+ Adults who Have Failed Two or More Highly Active Antiretroviral Regimens (HAART).
Co-investigator
25. A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of) Trizivir (Abacavir 300mg, Lamivudine 150 mg and Zidovudine 300 mg BID vs. Combivir (Lamivudine 150 mg and Zidovudine 300 mg BID plus Atazanavir 400 mg QD in Antiretroviral Naïve HIV-1 Infected Subjects over 48 Weeks. **Co-investigator**
26. A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy Compared to Open-label Current Protease Inhibitor Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 weeks with Long-Term Evaluation (> 48 weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected GW640385/Ritonavir Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen. **Co-investigator**
27. Sustiva™ (efavirenz) Expanded Access Program Protocol No. DMP 266-903. An Abacavir (1592U89) Open Label Protocol for Adult Patients with HIV-1 Infection Part B, Protocol No. CNA/3008. **Co-investigator**
28. Amprenavir (141W94) Open Label Protocol for Subjects with HIV-1 Infection who Have Experienced Treatment Failure or Are Intolerant to Previous Protease Inhibitor Therapy, Protocol PRO30010. **Co-investigator**
29. An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects with HIV-I Infection who are Failing their Current Antiretroviral Treatment Regime.
Co-investigator
30. An Open-Label Study to Evaluate the Safety and Tolerance of Amprenavir(141W94) Combination Therapy in Protease Inhibitor Experienced Subjects who are Intolerant (Hyperlipidemia with or without Lipodystrophy) but not Failing their Current Protease Inhibitor Therapy. **Co-investigator**
31. A Randomized, Open-Label, Expanded Access Program to Evaluate the Safety of Preveon (Adefovir dipivoxil) at Two Dose Levels When Used in Combination with other Anti-retroviral Agents for the Treatment of Patients with HIV Infection who Have Limited Treatment Options. **Co-investigator**

32. A Retrospective Case-Control Study to Investigate Genetic Polymorphisms in HIV Infected Subjects Who Developed Hypersensitivity Following Treatment with Abacavir; CNA30032. **Co-investigator**
33. Protocol NR 15720/M161027 – An Open Label, Randomized, Multicenter Study to Evaluate Fortavase (saquinavir) SGC QD, Norvir (ritonavir) QD Plus Two NRTIs vs Sustiva (efavirenz) QD Plus Two NRTIs in HIV Infected patients. **Co-investigator**
34. Randomized, Open Label, Comparative Safety and Efficacy Study of Tipranavir Boosted with Low Dose Ritonavir (TPV/RTV) versus Genotypically-defined Protease Inhibitor/Ritonavir in Multiple Antiretroviral Drug-experienced Patients.
Co-investigator